Use of Rolling Review for EUA Applications – pharmaceutical regulatory Use of Rolling Review for EUA Applications under Emergency Use Authorization (EUA) The landscape of pharmaceutical regulatory frameworks has evolved significantly, especially in the context of Emergency Use Authorization (EUA). The Rolling Review process allows for a dynamic approach to regulatory submissions, which can accelerate the availability of critical medical products during public health emergencies. This guide will walk you through the various stages of utilizing the Rolling Review for EUA applications, detailing essential actions and documentation expectations for regulatory professionals in the pharmaceutical sector. Understanding Rolling Review: A Regulatory…

How to Transition from EUA to Full Approval – pharmaceutical regulator How to Transition from EUA to Full Approval – Pharmaceutical Regulator The transition from Emergency Use Authorization (EUA) to full approval is a critical phase for pharmaceutical products, especially in the context of public health emergencies. This full approval signifies that a product has met all regulatory standards, ensuring its safety, efficacy, and quality. This comprehensive guide outlines a step-by-step process for regulatory affairs professionals, clinical medical writers, and other stakeholders involved in this crucial transition. Step 1: Understand the Regulatory Framework for Full Approval Before commencing the transition…

Regulatory Challenges Faced During COVID-19 EUA Submissions – pharmaceutical regulatory Regulatory Challenges Faced During COVID-19 EUA Submissions Step 1: Understanding the Emergency Use Authorization (EUA) The Emergency Use Authorization (EUA) is a mechanism that allows the FDA and similar global bodies to facilitate the availability and use of medical countermeasures, including vaccines and therapeutics, during public health emergencies like the COVID-19 pandemic. For pharmaceutical companies, understanding the specific requirements and processes inherent to the EUA is fundamental. The key regulatory challenge is that the EUA is not a full approval; it is a temporary measure. Hence, understanding how an EUA…

Risk-Benefit Assessment in EUA Granting – pharmaceutical regulatory Risk-Benefit Assessment in EUA Granting: A Step-by-Step Tutorial Guide The Emergency Use Authorization (EUA) is a critical regulatory mechanism that allows for the swift deployment of medical products during public health emergencies. The assessment of risk and benefit is pivotal in the process of granting an EUA, as it determines whether the product’s availability can save lives despite inherent uncertainties. This guide aims to provide pharmaceutical regulatory professionals with a comprehensive overview of the steps involved in conducting a risk-benefit assessment for EUAs, including dossier structure, necessary data, evaluation timelines, and regulatory…

Role of the ASEAN Pharmaceutical Product Working Group (PPWG) – regulatory agencies for pharmaceutical Role of the ASEAN Pharmaceutical Product Working Group (PPWG) – regulatory agencies for pharmaceutical The pharmaceutical landscape in the ASEAN region is evolving rapidly, influenced by technological advancements, globalization, and the push for regulatory harmonization. At the forefront of this initiative is the ASEAN Pharmaceutical Product Working Group (PPWG), which plays a pivotal role in establishing regulatory frameworks that guide pharmaceutical product development, approval, and monitoring in the region. This article provides a comprehensive step-by-step tutorial on the role of the PPWG and the critical regulatory…

EUA for Diagnostic Kits, Vaccines, and Therapeutics – pharmaceutical regulator EUA for Diagnostic Kits, Vaccines, and Therapeutics This step-by-step tutorial provides a comprehensive guide on obtaining Emergency Use Authorization (EUA) for diagnostic kits, vaccines, and therapeutics. It outlines the necessary documentation, timelines, and expectations from both a regulatory and administrative perspective, with reference to the global landscape including FDA, EMA, MHRA, and other relevant authorities. Step 1: Understanding the EUA Framework The Emergency Use Authorization (EUA) framework allows for the expedited availability of medical products during public health emergencies. It was first granted in the US under the Federal Food,…

Post-EUA Surveillance and Pharmacovigilance Obligance – regulatory medical writing Post-EUA Surveillance and Pharmacovigilance Obligations – Regulatory Medical Writing The Emergency Use Authorization (EUA) pathway has been instrumental in expediting access to critical medical products during public health emergencies. However, post-EUA obligations, particularly in terms of surveillance and pharmacovigilance, are vital to ensure the continued safety and efficacy of authorized products. This tutorial presents a detailed, step-by-step approach to understanding and implementing regulatory medical writing duties associated with post-EUA surveillance and pharmacovigilance. Step 1: Understanding Post-EUA Surveillance Requirements After a product receives EUA, regulatory authorities such as the FDA, EMA, or…

Global Comparison: EUA Mechanisms in India, EU, WHO – regulatory pharma Global Comparison: EUA Mechanisms in India, EU, WHO This article provides a comprehensive, step-by-step guide on Emergency Use Authorization (EUA) mechanisms as they pertain to regulatory pharma professionals in India, the European Union (EU), and the World Health Organization (WHO). It emphasizes the documentation expectations, timelines, and practical actions required through each phase of the regulatory pathway. Step 1: Understanding the Concept of Emergency Use Authorization Emergency Use Authorization (EUA) serves as a regulatory mechanism that allows for the swift approval of medical products during public health emergencies. These…

Revocation or Withdrawal of EUA: What Happens Next? – regulatory pharmacy Revocation or Withdrawal of EUA: What Happens Next? The Emergency Use Authorization (EUA) pathway offers a mechanism for expediting the availability of medical products during public health emergencies. However, the revocation or withdrawal of an EUA can occur under various circumstances. This tutorial provides a detailed, step-by-step guide for regulatory and clinical professionals in the pharmaceutical industry, with a focus on what happens when an EUA is revoked or withdrawn. It addresses the necessary documentation, regulatory expectations, and actions required to comply with various guidelines from key regulatory bodies…

ASEAN Cosmetic Directive and Its Impact on Product Registration – pharmaceutical regulatory agencies ASEAN Cosmetic Directive and Its Impact on Product Registration Step 1: Understanding the ASEAN Cosmetic Directive The ASEAN Cosmetic Directive (ACD) provides a harmonized approach to the regulation of cosmetic products across the ASEAN member states. This directive is instrumental in establishing a common framework for product approval and ensuring consumer safety. It is crucial for professionals involved in regulatory affairs to familiarize themselves with this directive, as it sets the tone for compliance and product registration within the region. Under the ACD, a cosmetic product is…